ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation biomedical technology, announced today that Biophan Europe GmbH has reported a series of important operational achievements for the year ended December 31, 2005. Dr. Michael Friebe, CEO of Biophan Europe, highlighted the Company's progress in developing proprietary solutions that enable fully compatible Magnetic Resonance Imaging (MRI) of stent based medical devices such as heart valves, coronary and peripheral stents, and vena cava filters, as well as new honors and recognitions that it has received.

"We are pleased to report that 2005 was a year marked by substantial new accomplishments in meeting our biomedical mission and overall strategic objectives," said Dr. Friebe. "Following our reorganization as a European subsidiary of Biophan Technologies in May, we have continued to make very encouraging progress on several major development fronts. Our scientific team led by Chief Technology Officer, Dr. Andreas Melzer, has also received gratifying new recognition from the international scientific community in the last year."

Biophan Europe is a global leader in developing modification technologies to make a range of implanted devices clearly imageable with MRI systems. In general, MRI is considered a superior imaging technology compared to relatively risky and invasive alternatives, including catheter labs and X-ray machines. Biophan Europes development program could dramatically improve interventional MRI and further enable minimally invasive surgical procedures. Currently, many implantable and surgical devices comprised of metal are contraindicated for use with MRI. In order to extend MRI to additional patients who need it, Biophan Europe has developed a variety of patented resonant circuit technologies to enable MRI imaging techniques to look "inside" stents and other implants, and to enable the MRI-guided implantation of the devices. Developed under the stewardship of Dr. Melzer, these potentially revolutionary capabilities would make virtually any stent fully visible with MRI, accompanied by certain changes in device design or material and proprietary AMRIS technologies (AMRIS is the previously registered name of Biophan Europe).
In addition, Biophan Europe reported the following key accomplishments for 2005:
MRI-Visible Stent Design:
Biophan Europe facilitated an exclusive license for Biophan Technologies with leading German biomedical researchers, Dr. Arno Bcker and Dr. Alexander Ruebben, for their breakthrough stent technology enabling accurate MRI in or around metallic stents. Together with the existing technologies already held by Biophan, including those obtained through the Company's recent acquisition of AMRIS GmbH, the exclusive license with Dr. Bcker and Dr. Ruebben will give Biophan licensing ownership to two of the most viable methods to create artifact-free images of stents and implants with MRI.

More Voices